urea has been researched along with Schizophrenia in 33 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
Excerpt | Relevance | Reference |
---|---|---|
"The ADVANCE study was a phase 2, 26-week, randomised, double-blind, placebo-controlled study of pimavanserin in stable outpatients with schizophrenia aged 18-55 years with predominant negative symptoms." | 9.51 | Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. ( Abbs, B; Arango, C; Bugarski-Kirola, D; Fava, M; Liu, IY; Nasrallah, H; Stankovic, S, 2022) |
"These preliminary data show that urea appears to be an effective therapeutic approach for the polydipsiahyponatremia syndrome." | 9.11 | Treatment of the polydipsia-hyponatremia syndrome with urea. ( Decaux, G; Musch, W; Verhoeven, A, 2005) |
" One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT2A receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis." | 7.91 | Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019) |
"The ADVANCE study was a phase 2, 26-week, randomised, double-blind, placebo-controlled study of pimavanserin in stable outpatients with schizophrenia aged 18-55 years with predominant negative symptoms." | 5.51 | Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. ( Abbs, B; Arango, C; Bugarski-Kirola, D; Fava, M; Liu, IY; Nasrallah, H; Stankovic, S, 2022) |
"These preliminary data show that urea appears to be an effective therapeutic approach for the polydipsiahyponatremia syndrome." | 5.11 | Treatment of the polydipsia-hyponatremia syndrome with urea. ( Decaux, G; Musch, W; Verhoeven, A, 2005) |
" This review provides an overview of 5-HT receptor pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, which target the 5HT2C and 5HT2A receptors and provide new treatments for obesity and Parkinson's disease psychosis, respectively." | 4.89 | Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. ( Meltzer, HY; Roth, BL, 2013) |
"Pimavanserin tartrate is the first 5-HT(2A) inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia." | 4.84 | Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. ( Abbas, A; Roth, BL, 2008) |
" One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT2A receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis." | 3.91 | Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019) |
" phencyclidine (PCP), produces prolonged impairment of novel object recognition (NOR), suggesting they constitute a hypoglutamate-based model of cognitive impairment in schizophrenia (CIS)." | 3.81 | Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. ( Horiguchi, M; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L, 2015) |
"N-methyl-D-aspartate (NMDA) receptor open channel blockers phencyclidine (PCP) and dizocilpine (MK-801) elicit schizophrenia-like symptoms in humans and in animal models." | 3.74 | Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. ( Deutsch, SI; Kozikowski, AP; Krolikowski, KA; Long, K; Mastropaolo, J; Monteiro, AC; Neale, JH; Olszewski, RT; Wegorzewska, MM; Zhou, J, 2008) |
"Phencyclidine (PCP) administration elicits positive and negative symptoms that resemble those of schizophrenia and is widely accepted as a model for the study of this human disorder." | 3.72 | NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. ( Barton, FB; Bukhari, N; Bzdega, T; Kozikowski, AP; Neale, JH; Olszewski, RT; Shamimi-Noori, S; Vicini, S; Wroblewska, B; Wroblewski, JT; Zhou, J, 2004) |
"risperidone (RIS), produce more extensive blockade of brain serotonin (5-HT)(2A) than dopamine (DA) D(2) receptors." | 2.77 | Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. ( Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM, 2012) |
" By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
"Pimavanserin is an antipsychotic with a unique mechanism of action (5-HT2A receptor inverse agonist) and no measurable dopaminergic activity; it has been demonstrated to be efficacious, well tolerated and safe for the treatment of PDP." | 2.53 | Pimavanserin for the treatment of Parkinson's disease psychosis. ( Chendo, I; Ferreira, JJ, 2016) |
" Further study is needed to determine whether these results concerning mechanism and dosage can be the basis for prevention of the development of CIS in at risk populations." | 1.38 | Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. ( Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (33.33) | 18.7374 |
1990's | 1 (3.03) | 18.2507 |
2000's | 9 (27.27) | 29.6817 |
2010's | 11 (33.33) | 24.3611 |
2020's | 1 (3.03) | 2.80 |
Authors | Studies |
---|---|
Bugarski-Kirola, D | 1 |
Arango, C | 1 |
Fava, M | 1 |
Nasrallah, H | 1 |
Liu, IY | 1 |
Abbs, B | 1 |
Stankovic, S | 1 |
Nasrallah, HA | 1 |
Fedora, R | 1 |
Morton, R | 1 |
Meltzer, HY | 4 |
Roth, BL | 2 |
Oyamada, Y | 1 |
Horiguchi, M | 2 |
Rajagopal, L | 1 |
Miyauchi, M | 1 |
Chendo, I | 1 |
Ferreira, JJ | 1 |
Abbas, A | 1 |
Bach, DR | 1 |
Herdener, M | 1 |
Grandjean, D | 1 |
Sander, D | 1 |
Seifritz, E | 1 |
Strik, WK | 1 |
Kawai, N | 1 |
Ishikawa, K | 1 |
Nemoto, K | 1 |
Katano, T | 1 |
Takahashi, S | 1 |
Hori, T | 1 |
Asada, T | 1 |
Baig, BJ | 1 |
Whalley, HC | 1 |
Hall, J | 1 |
McIntosh, AM | 1 |
Job, DE | 1 |
Cunningham-Owens, DG | 1 |
Johnstone, EC | 1 |
Lawrie, SM | 1 |
Profaci, CP | 2 |
Krolikowski, KA | 2 |
Olszewski, RT | 4 |
Neale, JH | 4 |
Marquis, KL | 1 |
Comery, TA | 1 |
Jow, F | 1 |
Navarra, RL | 1 |
Grauer, SM | 1 |
Pulicicchio, C | 1 |
Kelley, C | 1 |
Brennan, JA | 1 |
Roncarati, R | 1 |
Scali, C | 1 |
Haydar, S | 1 |
Ghiron, C | 1 |
Terstappen, GC | 1 |
Dunlop, J | 1 |
Ebdrup, BH | 1 |
Rasmussen, H | 1 |
Arnt, J | 1 |
Glenthøj, B | 1 |
Hannaway, KE | 1 |
Adelekun, AE | 1 |
Jayathilake, K | 1 |
Janczura, KJ | 1 |
Ball, SR | 1 |
Madore, JC | 1 |
Lavin, KM | 1 |
Lee, JC | 1 |
Lee, MJ | 1 |
Der, EK | 1 |
Hark, TJ | 1 |
Farago, PR | 1 |
Bzdega, T | 2 |
Elkis, H | 1 |
Vanover, K | 1 |
Weiner, DM | 1 |
van Kammen, DP | 1 |
Peters, P | 1 |
Hacksell, U | 1 |
Edoute, Y | 1 |
Davids, MR | 1 |
Johnston, C | 1 |
Halperin, ML | 1 |
FAURE, H | 1 |
TSAUNE, MK | 1 |
BRUNE, GG | 1 |
HOHL, HH | 1 |
HIMWICH, HE | 1 |
CALWELL, WP | 1 |
JACOBSEN, M | 1 |
SKARBEK, A | 1 |
GALLANT, DM | 2 |
BISHOP, MP | 2 |
SPREHE, D | 1 |
SHELTON, W | 1 |
Bukhari, N | 1 |
Zhou, J | 2 |
Kozikowski, AP | 2 |
Wroblewski, JT | 1 |
Shamimi-Noori, S | 1 |
Wroblewska, B | 1 |
Vicini, S | 1 |
Barton, FB | 1 |
Jones, HM | 1 |
Brammer, MJ | 1 |
O'Toole, M | 1 |
Taylor, T | 1 |
Ohlsen, RI | 1 |
Brown, RG | 1 |
Purvis, R | 1 |
Williams, S | 1 |
Pilowsky, LS | 1 |
Verhoeven, A | 1 |
Musch, W | 1 |
Decaux, G | 1 |
Wegorzewska, MM | 1 |
Monteiro, AC | 1 |
Long, K | 1 |
Mastropaolo, J | 1 |
Deutsch, SI | 1 |
Poyurovsky, M | 1 |
Weizman, R | 1 |
Weizman, A | 1 |
Tsygankov, BD | 1 |
Goldman, MB | 1 |
Robertson, GL | 1 |
Luchins, DJ | 1 |
Hedeker, D | 1 |
Gründig, E | 1 |
Weiss, J | 1 |
Itil, TM | 1 |
Herrmann, WM | 1 |
Akpinar, S | 1 |
Laithwaite, JA | 1 |
Berkó, G | 1 |
Durkó, I | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia[NCT02970305] | Phase 2 | 403 participants (Actual) | Interventional | 2016-11-04 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The CGI-SCH-I is a clinician-rated, 7-point scale to evaluate change from baseline in positive, negative, depressive, cognitive symptoms and overall severity in schizophrenia. For the purpose of this study, only the changes in negative symptoms from baseline were evaluated. The score could range from 1 (very much improved) to 7 (very much worse). (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) |
---|---|
Pimavanserin | 3.1 |
Placebo | 3.1 |
"The CGI-SCH-I is a clinician-rated, 7-point scale that is designed to evaluate change from baseline in positive, negative, depressive, cognitive symptoms and overall severity in schizophrenia. For the purpose of this study, only the changes in negative symptoms from baseline were evaluated. The 7-point scores range from 1 (very much improved) to 7 (very much worse); responders were defined as those with CGI-SCH-I of 1 or 2.~The analysis includes observed cases; missing cases were not imputed." (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | Participants (Count of Participants) |
---|---|
Pimavanserin | 47 |
Placebo | 40 |
The NSA-16 is a semi-structured interview and a validated scale containing 16 items for evaluating negative symptoms of schizophrenia, i.e. the reduction or absence of emotional expression and volitional behaviors normally present in a healthy person. Items are scored based on behaviors during the interview (items 1-4, 6, 7, 9, 11, 15, 16) or previous 7 days (items 5, 8, 10, 12-14) on a 6-point scale from 1 to 6. The NSA-16 domain scores are the sum of item scores in each domain i.e. communication (min score 4, max score 24), emotion/affect (min 3, max 18), social involvement (min 3, max 18), motivation (min 4, max 24), and retardation (min 2, max 12); with higher scores denoting more severe negative symptoms in schizophrenia. (NCT02970305)
Timeframe: From baseline (BL) to Week 26
Intervention | score on a scale (Mean) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Communication, BL | Communication, CFB to Week 26 | Emotion/affect, BL | Emotion/affect, CFB to Week 26 | Social Involvement, BL | Social Involvement, CFB to Week 26 | Motivation, BL | Motivation, CFB to Week 26 | Retardation, BL | Retardation, CFB to Week 26 | |
Pimavanserin | 12.3 | -2.4 | 12.7 | -1.9 | 13.1 | -2.0 | 16.7 | -2.6 | 7.0 | -1.7 |
Placebo | 12.3 | -2.0 | 12.5 | -1.6 | 12.6 | -1.4 | 16.6 | -2.2 | 7.0 | -1.5 |
The PANSS is a 30-item scale to evaluate the presence, absence, and severity of schizophrenia symptoms. Items are scored over the past week (7 days) on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS has 3 subscales that are the sums of the respective item scores, including the positive scale (min 7, max 49), negative scale (min 7, max 49), and general psychopathology scale (min 16, max 112). Higher scores denote more severe symptoms. (NCT02970305)
Timeframe: From baseline (BL) to Week 26
Intervention | score on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Positive subscale, BL | Positive subscale, CFB to Week 26 | Negative subscale, BL | Negative subscale, CFB to Week 26 | General psychopathology subscale, BL | General psychopathology subscale, CFB to Week 26 | |
Pimavanserin | 13.1 | -0.6 | 27.5 | -4.0 | 36.6 | -4.1 |
Placebo | 13.7 | -0.8 | 27.5 | -3.8 | 38.2 | -4.0 |
"The DAI-10 contains 6 items (1, 3, 4, 7, 9, and 10) that a subject who is fully adherent to the prescribed medication would answer as True and 4 items (2, 5, 6, and 8) that a subject who is fully adherent to the prescribed medication would answer as False. A correct answer is scored +1 and an incorrect answer is scored -1. The total score is the sum of pluses and minuses, which can range from -10 to 10 in increments of 2. A positive total score indicates a positive subjective response (adherent) and a negative total score indicates a negative subjective response (non-adherent). Higher scores denote better adherence." (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 5.7 | 0.2 |
Placebo | 5.7 | 0.2 |
The BACS is a performance-based assessment of treatment-related changes in cognition, assessing 6 domains of verbal memory and learning; working memory; motor function; verbal fluency; attention and speed of processing; and executive function. The 6 domains with their raw scores are: verbal memory 0-75; digit sequencing 0-28; token motor 0-100; verbal fluency 0-225; symbol coding 0-110; Tower of London 0-22. For each domain, higher scores reflect better cognition. Raw scores are converted to age and sex-corrected normalized scores. The BACS composite score is calculated as the mean of the normalized scores from the 6 subscale scores, standardized so that the mean of the BACS composite score in the healthy normative sample is 50 and the standard deviation is 10. (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 22.94 | 3.33 |
Placebo | 20.99 | 4.16 |
The KSS is a self-reported subjective measure of a subject's level of drowsiness. Respondents must choose statements that most accurately describe their level of sleepiness over the past 7 days. Scoring was based on a 9-point verbally anchored scale ranging from 1 (extremely alert) to 9 (very sleepy, great effort to keep awake, fighting sleep). Higher scores denoted more drowsiness. (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 4.6 | -0.3 |
Placebo | 4.8 | -0.6 |
The global negative symptoms rating of the NSA-16 assesses overall severity on a 7-point scale from 1 to 7, with higher scores denoting more severe negative symptoms in schizophrenia. (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 4.7 | -0.7 |
Placebo | 4.8 | -0.7 |
The CGI-SCH-S is a clinician-rated, 7-point scale to evaluate positive, negative, depressive, cognitive symptoms and overall severity in schizophrenia. For the purpose of this study, only the negative symptoms were evaluated. The score could range from 1 (normal, not ill) to 7 (among the most severely ill). (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 4.6 | -0.6 |
Placebo | 4.7 | -0.6 |
The NSA-16 is a semi-structured interview and a validated scale containing 16 items for evaluating negative symptoms of schizophrenia, i.e. the reduction or absence of emotional expression and volitional behaviors normally present in a healthy person. Items are scored based on behaviors during the interview (items 1-4, 6, 7, 9, 11, 15, 16) or previous 7 days (items 5, 8, 10, 12-14) on a 6-point scale from 1 to 6. The NSA-16 total score is the sum of item scores. It can range from 16 to a maximum of 96, with higher scores denoting more severe negative symptoms in schizophrenia. (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 61.8 | -10.5 |
Placebo | 61.0 | -8.8 |
"The PSP is a validated 100-point (1 to100) single-item rating scale to assess the psychosocial functioning of subjects with schizophrenia. Ratings are based on 4 main areas i.e. (a) socially useful activities, including work and study; (2) personal and social relationships, (3) self-care; and (4) disturbing and aggressive behaviors. The time period assessed is past month. Higher scores denote better psychosocial functioning" (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 47.2 | 8.1 |
Placebo | 46.7 | 8.4 |
The PANSS is a 30-item scale to evaluate the presence, absence, and severity of schizophrenia symptoms. Items are scored over the past week (7 days) on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS total score is the sum of scores and ranges from a minimum of 30 to a maximum of 210. Higher scores denote more severe symptoms. (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline to Week 26 | |
Pimavanserin | 77.2 | -8.7 |
Placebo | 79.4 | -8.6 |
"The NSA-16 is a semi-structured interview and a validated scale containing 16 items for evaluating negative symptoms of schizophrenia, i.e. the reduction or absence of emotional expression and volitional behaviors normally present in a healthy person. Items are scored based on behaviors during the interview (items 1-4, 6, 7, 9, 11, 15, 16) or previous 7 days (items 5, 8, 10, 12-14) on a 6-point scale from 1 to 6. The NSA-16 total score is the sum of item scores. It can range from 16 to a maximum of 96, with higher scores denoting more severe negative symptoms in schizophrenia.~NSA-16 responders were defined as patients with at least 20, 30, 50, or 75% percentage improvement in NSA-16 total score from baseline." (NCT02970305)
Timeframe: From baseline to Week 26
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
At least 20% improvement | At least 30% improvement | At least 50% improvement | At least 75% improvement | |
Pimavanserin | 93 | 56 | 21 | 4 |
Placebo | 84 | 51 | 16 | 2 |
4 reviews available for urea and Schizophrenia
Article | Year |
---|---|
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.
Topics: Benzazepines; Diabetes Mellitus, Type 2; Heart Valve Diseases; Humans; Molecular Structure; Obesity; | 2013 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Schizophrenia; Se | 2016 |
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Topics: Clinical Trials as Topic; Humans; Molecular Structure; Parkinson Disease; Piperidines; Schizophrenia | 2008 |
Serotonin 2A receptor antagonists for treatment of schizophrenia.
Topics: Antipsychotic Agents; Brain; Fluorobenzenes; Humans; Phenols; Piperidines; Positron-Emission Tomogra | 2011 |
6 trials available for urea and Schizophrenia
Article | Year |
---|---|
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
Topics: Adolescent; Adult; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; North America; Ou | 2022 |
Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia.
Topics: Administration, Oral; Adult; Humans; Hyponatremia; Male; Middle Aged; Schizophrenia; Syndrome; Thirs | 2009 |
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2012 |
Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Brain Mapping; Carbamide Peroxide; Ce | 2004 |
Treatment of the polydipsia-hyponatremia syndrome with urea.
Topics: Administration, Oral; Adult; Aged; Body Weight; Circadian Rhythm; Comorbidity; Creatine; Drinking; D | 2005 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
23 other studies available for urea and Schizophrenia
Article | Year |
---|---|
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Delusions; Drug Resistance; Female; Hallucinations; Hu | 2019 |
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol | 2015 |
Altered lateralisation of emotional prosody processing in schizophrenia.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Brain Mapping; Carbamide Peroxide; Cerebral Corte | 2009 |
Functional magnetic resonance imaging of BDNF val66met polymorphism in unmedicated subjects at high genetic risk of schizophrenia performing a verbal memory task.
Topics: Brain Mapping; Brain-Derived Neurotrophic Factor; Carbamide Peroxide; Cerebral Cortex; Genotype; Hum | 2010 |
Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.
Topics: Animals; Bridged Bicyclo Compounds; Dextroamphetamine; Disease Models, Animal; Dose-Response Relatio | 2011 |
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Avoidance Learning; Cognitio | 2011 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Halo | 2012 |
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose | 2012 |
An integrative physiological approach to polyuria and hyponatraemia: a 'double-take' on the diagnosis and therapy in a patient with schizophrenia.
Topics: Adult; Diabetes Insipidus; Diagnosis, Differential; Diuresis; Humans; Hyponatremia; Male; Polyuria; | 2003 |
[Contribution to the study of catatonia].
Topics: Body Fluids; Catatonia; Humans; Indicators and Reagents; Schizophrenia; Urea; Urine | 1953 |
[DATA ON THE PROBLEM OF THE PRESENCE OF MACHT'S PHYTOTOXIC REACTION IN SCHIZOPHRENIC PATIENTS].
Topics: Ammonia; Blood Proteins; Erythrocytes; Humans; Nitrogen; Plants; Schizophrenia; Urea | 1963 |
URINARY EXCRETION OF BUFOTENIN-LIKE SUBSTANCE IN PSYCHOTIC PATIENTS.
Topics: 1-Propanol; Acetates; Alcohols; Alkaloids; Ammonia; Bufotenin; Chromatography; Hallucinogens; Humans | 1963 |
A COMPARATIVE STUDY OF OXYPERTINE AND TRIFLUOPERAZINE IN CHRONIC SCHIZOPHRENIA--A NEW APPLICATION OF THE WING RATING SCALE.
Topics: Aggression; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Behavior; Blood | 1964 |
TPS-23: A NEW THIORIDAZINE DERIVATIVE.
Topics: Blood Cell Count; Blood Urea Nitrogen; Drug Therapy; Electrocardiography; Humans; Liver Function Tes | 1965 |
A PILOT TRIAL OF CI-515 IN SCHIZOPHRENIC PATIENTS.
Topics: Blood Cell Count; Blood Urea Nitrogen; Drug Therapy; Electrocardiography; Guanidine; Guanidines; Liv | 1965 |
NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR.
Topics: Animals; Behavior, Animal; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Glutamate Car | 2004 |
Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.
Topics: Agonistic Behavior; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dizocil | 2008 |
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonis | 2008 |
[Modified variant of simultaneous discontinuation of psychotropic drugs (given in combination with diuretics) as a method of abrupt termination therapy for protracted episodes of schizophrenia].
Topics: Acute Disease; Diuretics; Furosemide; Humans; Mannitol; Periodicity; Psychotropic Drugs; Schizophren | 1980 |
The influence of polydipsia on water excretion in hyponatremic, polydipsic, schizophrenic patients.
Topics: Adult; Blood Glucose; Blood Pressure; Creatinine; Female; Humans; Hyponatremia; Male; Middle Aged; P | 1996 |
[The influence of neuroleptic drugs on urinary excretion of non-protein nitrogen (author's transl)].
Topics: Amino Acids; Clopenthixol; Clozapine; Creatinine; Delayed-Action Preparations; Flupenthixol; Fluphen | 1976 |
Letter: Paraquat poisoning treated with immunosuppressants and potassium aminobenzoate.
Topics: Adult; Aminobenzoates; Azathioprine; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Paraq | 1975 |
A new possibility for the demonstration of -amino-laevulinic acid in urine on the basis of Mauzerall-Granick method.
Topics: Acute Disease; Aldehydes; Animals; Benzene Derivatives; Charcoal; Humans; Levulinic Acids; Methods; | 1972 |